Literature DB >> 15649567

Lethal mutagenesis of HIV.

Robert A Smith1, Lawrence A Loeb, Bradley D Preston.   

Abstract

HIV-1 and other retroviruses exhibit mutation rates that are 1,000,000-fold greater than their host organisms. Error-prone viral replication may place retroviruses and other RNA viruses near the threshold of "error catastrophe" or extinction due to an intolerable load of deleterious mutations. Strategies designed to drive viruses to error catastrophe have been applied to HIV-1 and a number of RNA viruses. Here, we review the concept of extinguishing HIV infection by "lethal mutagenesis" and consider the utility of this new approach in combination with conventional antiretroviral strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15649567     DOI: 10.1016/j.virusres.2004.11.011

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  32 in total

1.  Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations.

Authors:  Michael R Jordan; Mary Kearney; Sarah Palmer; Wei Shao; Frank Maldarelli; Eoin P Coakley; Colombe Chappey; Christine Wanke; John M Coffin
Journal:  J Virol Methods       Date:  2010-05-06       Impact factor: 2.014

2.  Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

Authors:  Rahul M Kohli; Robert W Maul; Amy F Guminski; Rhonda L McClure; Kiran S Gajula; Huseyin Saribasak; Moira A McMahon; Robert F Siliciano; Patricia J Gearhart; James T Stivers
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

3.  Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1.

Authors:  Christine L Clouser; Colleen M Holtz; Mary Mullett; Daune L Crankshaw; Jacquie E Briggs; M Gerard O'Sullivan; Steven E Patterson; Louis M Mansky
Journal:  Antimicrob Agents Chemother       Date:  2012-01-23       Impact factor: 5.191

4.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

Review 5.  Examining the theory of error catastrophe.

Authors:  Jesse Summers; Samuel Litwin
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli.

Authors:  Erick Denamur; Olivier Tenaillon; Catherine Deschamps; David Skurnik; Esthel Ronco; Jean Louis Gaillard; Bertrand Picard; Catherine Branger; Ivan Matic
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

7.  5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.

Authors:  Jonathan M Rawson; Richard H Heineman; Lauren B Beach; Jessica L Martin; Erica K Schnettler; Michael J Dapp; Steven E Patterson; Louis M Mansky
Journal:  Bioorg Med Chem       Date:  2013-08-20       Impact factor: 3.641

8.  Lethal mutagenesis of bacteria.

Authors:  James J Bull; Claus O Wilke
Journal:  Genetics       Date:  2008-09-09       Impact factor: 4.562

9.  Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.

Authors:  James I Mullins; Laura Heath; James P Hughes; Jessica Kicha; Sheila Styrchak; Kim G Wong; Ushnal Rao; Alexis Hansen; Kevin S Harris; Jean-Pierre Laurent; Deyu Li; Jeffrey H Simpson; John M Essigmann; Lawrence A Loeb; Jeffrey Parkins
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

Review 10.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Authors:  Diarmaid Hughes; Dan I Andersson
Journal:  Nat Rev Genet       Date:  2015-07-07       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.